PRDM9 and glioblastoma: We also showed that AQB significantly enhanced 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, therapy in both orthotopic breast cancer and glioblastoma patient-derived xenograft (PDX) models.